Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment

References

• Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):117–124. doi:10.2174/1570161117666190502103733
   PubMed Web of Science ®Google Scholar
• Squadrito G, Cucinotta D. The late complications of diabetes mellitus. Ann Ital Med Int. 1991;6(1):126–136.
   PubMedGoogle Scholar
• Schlienger JL. Type 2 diabetes complications. Presse Med. 2013;42(5):839–848. doi:10.1016/j.lpm.2013.02.313
   PubMed Web of Science ®Google Scholar
• Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol. 2010;10(7):501–513. doi:10.1038/nri2787
   PubMed Web of Science ®Google Scholar
• Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(3):150–161. doi:10.1038/s41574-020-00443-4
   PubMed Web of Science ®Google Scholar
• Prevention CfDCa. National diabetes statistics report: what is Diabetes?; 2022. Available from: https://www.cdc.gov/diabetes/basics/diabetes.html. Accessed January 17, 2024
   Google Scholar
• Dash L, Bhasme P, Sumant O. Diabetes therapeutics market report; 2022. Available from: https://www.alliedmarketresearch.com/diabetes-therapeutics-market. Accessed January 17, 2024.
   Google Scholar
• S O. Fusion protein and biosimilars market report; 2023. Available from: https://www.alliedmarketresearch.com/fusion-protein-and-biosimilars-market-A12017. Accessed January 17, 2024.
   Google Scholar
• Geiser JS, Heathman MA, Cui X, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016;55(5):625–634. doi:10.1007/s40262-015-0338-3
   PubMed Web of Science ®Google Scholar
• Jimenez-Solem E, Rasmussen MH, Christensen M, Knop FK. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther. 2010;12(6):790–797.
   PubMedGoogle Scholar
• Yoo JH, Cho YK, Lee J, et al. Clinical efficacy and parameters affecting the response to dulaglutide treatment in patients with type 2 diabetes: a retrospective, real-world data study. Diabetes Ther. 2019;10(4):1453–1463. doi:10.1007/s13300-019-0658-7
   PubMed Web of Science ®Google Scholar
• Frias JP, Wynne AG, Matyjaszek-Matuszek B, et al. Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. Diabetes Obes Metab. 2019;21(9):2048–2057. doi:10.1111/dom.13764
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Sorli CH, Trautmann ME, et al. Once-weekly efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug naive, referenced to liraglutide. Diabetes Care. 2019;42(9):1733–1741. doi:10.2337/dc18-2648
   PubMed Web of Science ®Google Scholar
• Moyers JS, Hansen RJ, Day JW, et al. Preclinical characterization of LY3209590, a novel weekly basal insulin fc-fusion protein. J Pharmacol Exp Ther. 2022;382(3):346–355. doi:10.1124/jpet.122.001105
   PubMed Web of Science ®Google Scholar
• Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009;32(7):1244–1249. doi:10.2337/dc09-0054
   PubMed Web of Science ®Google Scholar
• Pan A, Gerriets V. Etanercept. In: StatPearls. Treasure Island (FL): StatPearls; 2023.
   Google Scholar
• Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94. doi:10.1136/annrheumdis-2013-203843
   PubMed Web of Science ®Google Scholar
• Harigai M, Ishiguro N, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of Abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2016;26(4):491–498. doi:10.3109/14397595.2015.1123211
   PubMed Web of Science ®Google Scholar
• Schreiber S, Aden K, Bernardes JP, et al. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160(7):2354–2366.e2311. doi:10.1053/j.gastro.2021.02.062
   PubMed Web of Science ®Google Scholar
• Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002;29(5–6):415–426. doi:10.1023/A:1022995602257
   PubMed Web of Science ®Google Scholar
• Rigby MR, DiMeglio LA, Rendell MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013;1(4):284–294. doi:10.1016/S2213-8587(13)70111-6
   PubMed Web of Science ®Google Scholar
• White PC, Adhikari S, Grishman EK, Sumpter KM. A phase I study of anti-inflammatory therapy with rilonacept in adolescents and adults with type 1 diabetes mellitus. Pediatr Diabetes. 2018;19(4):788–793. doi:10.1111/pedi.12634
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289–297. doi:10.1016/S2213-8587(13)70214-6
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev. 2011;27(6):528–542. doi:10.1002/dmrr.1202
   PubMed Web of Science ®Google Scholar
• Ahren B, Burke B. Using albumin to improve the therapeutic properties of diabetes treatments. Diabetes Obes Metab. 2012;14(2):121–129. doi:10.1111/j.1463-1326.2011.01482.x
   PubMed Web of Science ®Google Scholar
• Duttaroy A, Kanakaraj P, Osborn BL, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes. 2005;54(1):251–258. doi:10.2337/diabetes.54.1.251
   PubMed Web of Science ®Google Scholar
• Wang Y, Shao J, Zaro JL, Shen WC. Proinsulin-transferrin fusion protein as a novel long-acting insulin analog for the inhibition of hepatic glucose production. Diabetes. 2014;63(5):1779–1788. doi:10.2337/db13-0973
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. 2020;141(9):e139–e596. doi:10.1161/CIR.0000000000000757
   PubMed Web of Science ®Google Scholar
• Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol. 2018;19(1):31–44. doi:10.1038/nrm.2017.89
   PubMed Web of Science ®Google Scholar
• Lee J, Pilch PF. The insulin receptor: structure, function, and signaling. Am J Physiol. 1994;266(2):C319–334. doi:10.1152/ajpcell.1994.266.2.C319
   PubMedGoogle Scholar
• Mackenzie RW, Elliott BT. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014;7:55–64. doi:10.2147/DMSO.S48260
   PubMedGoogle Scholar
• Chen Y, Wang Y, Zhang J, et al. Rab10 and myosin-Va mediate insulin-stimulated GLUT4 storage vesicle translocation in adipocytes. J Cell Biol. 2012;198(4):545–560. doi:10.1083/jcb.201111091
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293–1300. doi:10.1038/nature08933
   PubMed Web of Science ®Google Scholar
• Russell WE, Bundy BN, Anderson MS, et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care. 2023;46(5):1005–1013. doi:10.2337/dc22-2200
   PubMed Web of Science ®Google Scholar
• Ehlers MR, Rigby MR. Targeting memory T cells in type 1 diabetes. Curr Diab Rep. 2015;15(11):84. doi:10.1007/s11892-015-0659-5
   PubMed Web of Science ®Google Scholar
• Bonifacio E, Achenbach P. Birth and coming of age of islet autoantibodies. Clin Exp Immunol. 2019;198(3):294–305. doi:10.1111/cei.13360
   PubMed Web of Science ®Google Scholar
• Hivert MF, Vassy JL, Meigs JB. Susceptibility to type 2 diabetes mellitus--from genes to prevention. Nat Rev Endocrinol. 2014;10(4):198–205. doi:10.1038/nrendo.2014.11
   PubMed Web of Science ®Google Scholar
• Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465–476. doi:10.1038/nrd4275
   PubMed Web of Science ®Google Scholar
• Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabet Res Clin Pract. 2014;105(2):141–150. doi:10.1016/j.diabres.2014.04.006
   PubMed Web of Science ®Google Scholar
• van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med. 2013;71(4):174–187.
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–1801. doi:10.1172/JCI29069
   PubMed Web of Science ®Google Scholar
• Kung YT, Du YC, Huang WT, Chen CC, Ke LT. Total synthesis of crystalline insulin. 科学通报:英文版 [Scientia Sinica]. 1966;15(4):544–561.
   PubMedGoogle Scholar
• Institute, Biockemistry, Sinica. Resynthesis of insulin from its A And B chains. Semi Month J Sci. 1966;06:246–246.
   Google Scholar
• Zhang Y. The first protein ever synthesized in vitro—a personal reminiscence of the total synthesis of crystalline insulin. Sci China. 2010;2010:1.
   Google Scholar
• Institute, Sinica, Department, Peking. The synthesis of the: a chain of insulin and partial synthesis of crystalline insulin from the synthetic A Chain and the natural B Chain. Chin. Sci. Bull. 1966;06:256–256.
   Google Scholar
• Mali S, Divekar M, Sumant O. Protein therapeutics market report; 2022. Available from: https://www.alliedmarketresearch.com/protein-therapeutics-market. Accessed January 17, 2024.
   Google Scholar
• Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40(12):1722–1760. doi:10.1038/s41587-022-01582-x
   PubMed Web of Science ®Google Scholar
• Zaman R, Islam RA, Ibnat N, et al. Current strategies in extending half-lives of therapeutic proteins. J Control Release. 2019;301:176–189. doi:10.1016/j.jconrel.2019.02.016
   PubMed Web of Science ®Google Scholar
• Story CM, Mikulska JE, Simister NE. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med. 1994;180(6):2377–2381. doi:10.1084/jem.180.6.2377
   PubMed Web of Science ®Google Scholar
• Nakamura A, Sosa A, Komori H, Kita A, Miki K. Crystal structure of TTHA1657 (AT-rich DNA-binding protein; p25) from Thermus thermophilus HB8 at 2.16 A resolution. Proteins. 2007;66(3):755–759. doi:10.1002/prot.21222
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–725. doi:10.1038/nri2155
   PubMed Web of Science ®Google Scholar
• Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The Neonatal Fc Receptor (FcRn): a Misnomer? Front Immunol. 2019;10:1540.
   PubMed Web of Science ®Google Scholar
• Kawabata H. Transferrin and transferrin receptors update. Free Radic Biol Med. 2019;133:46–54. doi:10.1016/j.freeradbiomed.2018.06.037
   PubMed Web of Science ®Google Scholar
• Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 2002;22(3):225–250. doi:10.1002/med.10008
   PubMed Web of Science ®Google Scholar
• Amet N, Wang W, Shen WC. Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J Control Release. 2010;141(2):177–182. doi:10.1016/j.jconrel.2009.09.007
   PubMed Web of Science ®Google Scholar
• Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018;8(6):916–931.
   PubMed Web of Science ®Google Scholar
• Okuyama T, Eto Y, Sakai N, et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol Ther. 2021;29(2):671–679. doi:10.1016/j.ymthe.2020.09.039
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451–1458. doi:10.1016/S1359-6446(05)03575-0
   PubMed Web of Science ®Google Scholar
• Strohl WR. Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. BioDrugs. 2015;29(4):215–239. doi:10.1007/s40259-015-0133-6
   PubMed Web of Science ®Google Scholar
• Yang X, Bartlett MG. Glycan analysis for protein therapeutics. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1120:29–40. doi:10.1016/j.jchromb.2019.04.031
   PubMed Web of Science ®Google Scholar
• Sola RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci. 2009;98(4):1223–1245. doi:10.1002/jps.21504
   PubMed Web of Science ®Google Scholar
• Borza B, Hajba L, Guttman A. N-glycan analysis in molecular medicine: innovator and biosimilar protein therapeutics. Curr Mol Med. 2020;20(10):828–839. doi:10.2174/1566524020999201203212352
   PubMed Web of Science ®Google Scholar
• Martins JP, Figueiredo P, Wang S, et al. Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium. Bioact Mater. 2021. doi:10.1016/j.bioactmat.2021.08.007
   PubMed Web of Science ®Google Scholar
• Miller MR, Raftis JB, Langrish JP, et al. Inhaled nanoparticles accumulate at sites of vascular disease. ACS nano. 2017;11(5):4542–4552. doi:10.1021/acsnano.6b08551
   PubMed Web of Science ®Google Scholar
• Mohammadpour R, Dobrovolskaia MA, Cheney DL, Greish KF, Ghandehari H. Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. Adv Drug Delivery Rev. 2019;2019:144.
   Google Scholar
• Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci. 2015;101(30):11076–11081. doi:10.1073/pnas.0402970101
   Google Scholar
• Ward ES, Ober RJ. Targeting FcRn to Generate Antibody-Based Therapeutics. Trends Pharmacol Sci. 2018;39(10):892–904. doi:10.1016/j.tips.2018.07.007
   PubMed Web of Science ®Google Scholar
• Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol. 2004;172(4):2021–2029. doi:10.4049/jimmunol.172.4.2021
   PubMed Web of Science ®Google Scholar
• Lohse S, Derer S, Beyer T, et al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol. 2011;186(6):3770–3778. doi:10.4049/jimmunol.1003082
   PubMed Web of Science ®Google Scholar
• Karagiannis SN, Josephs DH, Karagiannis P, et al. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother. 2012;61(9):1547–1564. doi:10.1007/s00262-011-1162-8
   PubMed Web of Science ®Google Scholar
• Elders RC, Holder A, Smith KC, Baines SJ, Catchpole B. Recombinant canine IgE Fc and an IgE Fc-TRAIL fusion protein bind to neoplastic canine mast cells. Vet Immunol Immunopathol. 2014;159(1–2):29–40. doi:10.1016/j.vetimm.2014.02.018
   PubMed Web of Science ®Google Scholar
• Perez-Witzke D, Miranda-García MA, Suárez N, Becerra R, Montano RF. CTLA4Fcε, a novel soluble fusion protein that binds B7 molecules and the IgE receptors, and reduces human in vitro sCD23 production and lymphocyte proliferation. Immunology. 2016;148(1):40–55. doi:10.1111/imm.12586
   PubMed Web of Science ®Google Scholar
• Ammann JU, Jahnke M, Dyson MR, Kaufman J, Trowsdale J. Detection of weak receptor-ligand interactions using IgM and J-chain-based fusion proteins. Eur J Immunol. 2012;42(5):1354–1356. doi:10.1002/eji.201142151
   PubMed Web of Science ®Google Scholar
• Bettoni S, Maziarz K, Stone M, et al. Serum complement activation by C4BP-IgM fusion protein can restore susceptibility to antibiotics in Neisseria gonorrhoeae. Front Immunol. 2021;12(3511). doi:10.3389/fimmu.2021.726801
   PubMedGoogle Scholar
• Kumar S, Singh VK, Vasam M, et al. An in vitro refolding method to produce oligomers of anti-CHIKV, E2-IgM Fc fusion subunit vaccine candidates expressed in E. coli. J Immunol Methods. 2020;487:112869. doi:10.1016/j.jim.2020.112869
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22(6):868–876. doi:10.1016/j.copbio.2011.06.012
   PubMed Web of Science ®Google Scholar
• Damelang T, Rogerson SJ, Kent SJ, Chung AW. Role of IgG3 in Infectious Diseases. Trends Immunol. 2019;40(3):197–211. doi:10.1016/j.it.2019.01.005
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Williams GT, Bindon CI, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med. 1987;166(5):1351–1361. doi:10.1084/jem.166.5.1351
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716–3725. doi:10.1182/blood-2008-09-179754
   PubMed Web of Science ®Google Scholar
• Honger G, Amico P, Arnold ML, Spriewald BM, Schaub S. Effects of weak/non-complement-binding HLA antibodies on C1q-binding. HLA. 2017;90(2):88–94. doi:10.1111/tan.13062
   PubMed Web of Science ®Google Scholar
• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007;7(9):1401–1413. doi:10.1517/14712598.7.9.1401
   PubMed Web of Science ®Google Scholar
• Mayo KE, Miller LJ, Bataille D, et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003;55(1):167–194. doi:10.1124/pr.55.1.6
   PubMed Web of Science ®Google Scholar
• Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300–1304. doi:10.1016/S0140-6736(87)91194-9
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824–830. doi:10.1016/S0140-6736(02)07952-7
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239–1246. doi:10.1210/jcem.87.3.8355
   PubMed Web of Science ®Google Scholar
• Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4):665–673. doi:10.1007/BF01316798
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439. doi:10.1152/physrev.00034.2006
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017;136(9):849–870. doi:10.1161/CIRCULATIONAHA.117.028136
   PubMed Web of Science ®Google Scholar
• Zimmerman RS, Hobbs TM, Wells BJ, et al. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system. Diabetes Obes Metab. 2017;19(11):1555–1561. doi:10.1111/dom.12969
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-The-art. Mol Metab. 2021;46:101102. doi:10.1016/j.molmet.2020.101102
   PubMed Web of Science ®Google Scholar
• Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovas Diabetol. 2022;21(1):1–16. doi:10.1186/s12933-022-01604-7
   PubMed Web of Science ®Google Scholar
• Chen K, Chen L, Shan Z, et al. Beinaglutide for weight management in Chinese individuals with overweight or obesity: a phase 3 randomized controlled clinical study. Diabetes Obes Metab. 2023;2023:1.
   Google Scholar
• Liu L, Ruan Z, Ung COL, et al. Long-term cost-effectiveness of subcutaneous once-weekly semaglutide versus polyethylene glycol loxenatide for treatment of type 2 diabetes mellitus in China. Diabetes Ther. 2023;14(1):93–107. doi:10.1007/s13300-022-01336-7
   PubMed Web of Science ®Google Scholar
• Bettge K, Kahle M, El Aziz MS A, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–347. doi:10.1111/dom.12824
   PubMed Web of Science ®Google Scholar
• Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol. 2022;13:1043789. doi:10.3389/fendo.2022.1043789
   PubMed Web of Science ®Google Scholar
• Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26(4):287–296. doi:10.1002/dmrr.1080
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Blevins T, Rosenstock J, Cheng C, Anderson J. The effect of LY2189265 (GLP-1 analogue) once weekly on HbA(1c) and beta cell function in uncontrolled type 2 diabetes mellitus: the EGO study analysis. Paper presented at: 45th Annual Meeting of the 2009; 2009.
   Google Scholar
• AdlP P, Loghin C, Cui X, et al. Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion. Diabetes Obesity Metab. 2017;2017:1.
   Google Scholar
• Wysham C, Blevins T, Arakaki R, et al. Erratum. efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159–2167. doi:10.2337/dc13-2760
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168–2176. doi:10.2337/dc13-2759
   PubMed Web of Science ®Google Scholar
• Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849–858. doi:10.1111/dom.12479
   PubMed Web of Science ®Google Scholar
• MacIsaac RJ. Dulaglutide and Insulin: how Can the AWARD Studies Help Guide Clinical Practice? Diabetes Ther. 2020;11(8):1627–1638. doi:10.1007/s13300-020-00863-5
   PubMed Web of Science ®Google Scholar
• Leung K. (99m)Tc-Hydrazinonicotinamide-aminohexanoic acid-Lys(40)-exendin-4. In: Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): MICAD; 2004.
   Google Scholar
• Yoon KH, Kang J, Kwon SC, et al. Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22(8):1292–1301. doi:10.1111/dom.14032
   PubMed Web of Science ®Google Scholar
• Pratley RE, Kang J, Trautmann ME, et al. Body weight management and safety with efpeglenatide in adults without diabetes: a Phase II randomized study. Diabetes Obes Metab. 2019;21(11):2429–2439. doi:10.1111/dom.13824
   PubMed Web of Science ®Google Scholar
• Del Prato S, Kang J, Trautmann ME, et al. Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. Diabetes Obes Metab. 2020;22(7):1176–1186. doi:10.1111/dom.14020
   PubMed Web of Science ®Google Scholar
• Hompesch M, Kang J, Han O, et al. Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. BMJ Open Diabetes Res Care. 2021;9(1):e002208. doi:10.1136/bmjdrc-2021-002208
   PubMed Web of Science ®Google Scholar
• Frias JP, Choi J, Rosenstock J, et al. Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial. Diabetes Care. 2022;45(7):1592–1600. doi:10.2337/dc21-2656
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Li Z, Ramasundarahettige C, et al. Exploring the relationship between efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: insights from the AMPLITUDE-O trial. Circulation. 2023;147(13):1004–1013. doi:10.1161/CIRCULATIONAHA.122.063716
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907. doi:10.1056/NEJMoa2108269
   PubMed Web of Science ®Google Scholar
• Pratley RE, Jacob S, Baek S, et al. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ Open Diabetes Res Care. 2022;10(1):e002207. doi:10.1136/bmjdrc-2021-002207
   PubMed Web of Science ®Google Scholar
• Moyers JS, Hansen RJ, Day JW, et al. Preclinical characterization of once weekly basal insulin Fc (BIF). J Endocrine Soc. 2021;5:A442–A442. doi:10.1210/jendso/bvab048.903
   Google Scholar
• Heise T, Chien J, Beals JM, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab. 2023;25(4):1080–1090. doi:10.1111/dom.14956
   PubMed Web of Science ®Google Scholar
• Frias J, Chien J, Zhang Q, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Lancet Diabetes Endocrinol. 2023;11(3):158–168. doi:10.1016/S2213-8587(22)00388-6
   PubMed Web of Science ®Google Scholar
• Kazda CM, Bue-Valleskey JM, Chien J, et al. Novel once-weekly basal insulin fc achieved similar glycemic control with a safety profile comparable to insulin degludec in patients with type 1 diabetes. Diabetes Care. 2023;46(5):1052–1059. doi:10.2337/dc22-2395
   PubMed Web of Science ®Google Scholar
• Bue-Valleskey JM, Kazda CM, Ma C, et al. Once-weekly basal insulin fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial. Diabetes Care. 2023;46(5):1060–1067. doi:10.2337/dc22-2396
   PubMed Web of Science ®Google Scholar
• Gilor C, Hulsebosch SE, Pires J, et al. An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats. J Vet Intern Med. 2021;35(5):2123–2130. doi:10.1111/jvim.16150
   PubMed Web of Science ®Google Scholar
• Hulsebosch SE, Pires J, Bannasch MJ, et al. Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs. J Vet Intern Med. 2022;36(4):1211–1219. doi:10.1111/jvim.16449
   PubMed Web of Science ®Google Scholar
• Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–452. doi:10.1146/annurev.iy.10.040192.002211
   PubMed Web of Science ®Google Scholar
• Al-Lamki RS, Mayadas TN. TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int. 2015;87(2):281–296. doi:10.1038/ki.2014.285
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409–2415. doi:10.1172/JCI117936
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271(5249):665–668. doi:10.1126/science.271.5249.665
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46(12):1594–1603. doi:10.1007/s00125-003-1228-z
   PubMed Web of Science ®Google Scholar
• Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2018;119(1):105–110. doi:10.1002/jcb.26174
   PubMed Web of Science ®Google Scholar
• Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis. 1999;58(Suppl 1):I65–69. doi:10.1136/ard.58.2008.i65
   PubMed Web of Science ®Google Scholar
• Di KB, Bahcivan E, Eser Faki H, Uney K. Combined treatment with interleukin-1 and tumor necrosis factor-alpha antagonists improve type 2 diabetes in rats. Can J Physiol Pharmacol. 2018;96(8):751–756. doi:10.1139/cjpp-2017-0769
   PubMed Web of Science ®Google Scholar
• Seriolo B, Ferrone C, Cutolo M. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol. 2008;35(2):355.
   PubMed Web of Science ®Google Scholar
• Corrao S, Pistone G, Scaglione R, Colomba D, Calvo L, Licata G. Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study. Clin Rheumatol. 2009;28(1):89–92. doi:10.1007/s10067-008-1026-6
   PubMed Web of Science ®Google Scholar
• Pfeifer EC, Saxon DR, Janson RW. Etanercept-induced hypoglycemia in a patient with psoriatic arthritis and diabetes. J Investig Med High Impact Case Rep. 2017;5(3):2324709617727760. doi:10.1177/2324709617727760
   Google Scholar
• Doria A, Niewczas MA, Fiorina P. Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol. 2012;32(5):437–444. doi:10.1016/j.semnephrol.2012.07.006
   PubMed Web of Science ®Google Scholar
• Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192(2):295–302. doi:10.1084/jem.192.2.295
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192(2):303–310. doi:10.1084/jem.192.2.303
   PubMed Web of Science ®Google Scholar
• Ise W, Kohyama M, Nutsch KM, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol. 2010;11(2):129–135. doi:10.1038/ni.1835
   PubMed Web of Science ®Google Scholar
• Rudd CE. The reverse stop-signal model for CTLA4 function. Nat Rev Immunol. 2008;8(2):153–160. doi:10.1038/nri2253
   PubMed Web of Science ®Google Scholar
• Haseda F, Imagawa A, Murase-Mishiba Y, et al. Low CTLA-4 expression in CD4+ helper T-cells in patients with fulminant type 1 diabetes. Immunol Lett. 2011;139(1–2):80–86. doi:10.1016/j.imlet.2011.05.003
   PubMed Web of Science ®Google Scholar
• Khalid Kheiralla KE. CTLA-4 (+49A/G) Polymorphism in Type 1 Diabetes Children of Sudanese Population. Glob Med Genet. 2021;8(1):11–18. doi:10.1055/s-0041-1723008
   PubMedGoogle Scholar
• Wang CJ, Schmidt EM, Attridge K, et al. Immune regulation by CTLA-4--relevance to autoimmune diabetes in a transgenic mouse model. Diabetes Metab Res Rev. 2011;27(8):946–950. doi:10.1002/dmrr.1277
   PubMed Web of Science ®Google Scholar
• Teng GG, Turkiewicz AM, Moreland LW. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2005;5(9):1245–1254. doi:10.1517/14712598.5.9.1245
   PubMed Web of Science ®Google Scholar
• Makino H, Kashihara N, Sugiyama H, et al. Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes. Diabetes. 1996;45(4):488–495. doi:10.2337/diab.45.4.488
   PubMed Web of Science ®Google Scholar
• Herrera M, Soderberg M, Sabirsh A, et al. Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease. Am J Physiol Renal Physiol. 2017;312(4):F748–F759. doi:10.1152/ajprenal.00179.2016
   PubMed Web of Science ®Google Scholar
• Fujii M, Inoguchi T, Batchuluun B, et al. CTLA-4Ig immunotherapy of obesity-induced insulin resistance by manipulation of macrophage polarization in adipose tissues. Biochem Biophys Res Commun. 2013;438(1):103–109. doi:10.1016/j.bbrc.2013.07.034
   PubMed Web of Science ®Google Scholar
• Ursini F, Russo E, Letizia Hribal M, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine. 2015;94(21):e888. doi:10.1097/MD.0000000000000888
   PubMed Web of Science ®Google Scholar
• Ursini F, Russo E, Ruscitti P, Giacomelli R, De Sarro G. The effect of non-TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritis. Autoimmun Rev. 2018;17(4):399–404. doi:10.1016/j.autrev.2017.11.030
   PubMed Web of Science ®Google Scholar
• Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with Abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:9789):412–419. doi:10.1016/S0140-6736(11)60886-6
   Web of Science ®Google Scholar
• Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375–3383. doi:10.1172/JCI57158
   PubMed Web of Science ®Google Scholar
• Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015;26(5):475–487. doi:10.1016/j.cytogfr.2015.07.004
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–888. doi:10.1016/j.bbamcr.2011.01.034
   PubMed Web of Science ®Google Scholar
• Wunderlich FT, Strohle P, Konner AC, et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 2010;12(3):237–249. doi:10.1016/j.cmet.2010.06.011
   PubMed Web of Science ®Google Scholar
• Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36(1):166–175. doi:10.2337/dc12-0702
   PubMed Web of Science ®Google Scholar
• Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018;26(3):685–698. doi:10.1007/s10787-018-0458-0
   PubMed Web of Science ®Google Scholar
• Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001;268(1):160–167. doi:10.1046/j.1432-1327.2001.01867.x
   PubMedGoogle Scholar
• Robinson R, Srinivasan M, Shanmugam A, et al. Interleukin-6 trans-signaling inhibition prevents oxidative stress in a mouse model of early diabetic retinopathy. Redox Biol. 2020;34:101574. doi:10.1016/j.redox.2020.101574
   PubMed Web of Science ®Google Scholar
• Yahagi K, Kolodgie FD, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017;37(2):191–204. doi:10.1161/ATVBAHA.116.306256
   PubMed Web of Science ®Google Scholar
• Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi Khalil C. Macrovascular complications in patients with diabetes and prediabetes. Biomed Res Int. 2017;2017:7839101. doi:10.1155/2017/7839101
   PubMed Web of Science ®Google Scholar
• Schulte DM, Waetzig GH, Schuett H, et al. Case report: arterial wall inflammation in atherosclerotic cardiovascular disease is reduced by olamkicept (sgp130Fc). Front Pharmacol. 2022;13:758233. doi:10.3389/fphar.2022.758233
   PubMed Web of Science ®Google Scholar
• Schuett H, Oestreich R, Waetzig GH, et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32(2):281–290. doi:10.1161/ATVBAHA.111.229435
   PubMed Web of Science ®Google Scholar
• Binder C, Cvetkovski F, Sellberg F, et al. CD2 Immunobiology. Front Immunol. 2020;11:1090. doi:10.3389/fimmu.2020.01090
   PubMed Web of Science ®Google Scholar
• Krueger GG. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin Biol Ther. 2002;2(4):431–441. doi:10.1517/14712598.2.4.431
   PubMed Web of Science ®Google Scholar
• Chamian F, Lin SL, Lee E, et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med. 2007;5:27. doi:10.1186/1479-5876-5-27
   PubMed Web of Science ®Google Scholar
• Pinckney A, Rigby MR, Keyes-Elstein L, Soppe CL, Nepom GT, Ehlers MR. Correlation among hypoglycemia, glycemic variability, and c-peptide preservation after alefacept therapy in patients with type 1 diabetes mellitus: analysis of data from the immune tolerance network T1DAL trial. Clin Ther. 2016;38(6):1327–1339. doi:10.1016/j.clinthera.2016.04.032
   PubMed Web of Science ®Google Scholar
• Ballak DB, Stienstra R, Tack CJ, Dinarello CA, van Diepen JA. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015;75(2):280–290. doi:10.1016/j.cyto.2015.05.005
   PubMed Web of Science ®Google Scholar
• Peiro C, Lorenzo O, Carraro R, Sanchez-Ferrer CF. IL-1beta inhibition in cardiovascular complications associated to diabetes mellitus. Front Pharmacol. 2017;8:363. doi:10.3389/fphar.2017.00363
   PubMed Web of Science ®Google Scholar
• Fava AM, Reyaldeen R, Lo Presti S, et al. Rilonacept for the treatment of recurrent pericarditis. Expert Opin Biol Ther. 2022;22(1):7–16. doi:10.1080/14712598.2022.2005024
   PubMed Web of Science ®Google Scholar
• Klein AL, Imazio M, Brucato A, et al. RHAPSODY: rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. Am Heart J. 2020;228:81–90. doi:10.1016/j.ahj.2020.07.004
   PubMed Web of Science ®Google Scholar
• Wang J, Zou T, Yang HX, et al. Insulin receptor binding motif tagged with IgG4 Fc (Yiminsu) works as an insulin sensitizer to activate Akt signaling in hepatocytes. Genet Mol Res. 2015;14(3):8819–8828. doi:10.4238/2015.August.3.5
   PubMed Web of Science ®Google Scholar
• Vico P, Dessy H. A case of lead poisoning in a rachitic child with pica. Critical review of the literature. Rev Med Brux. 1988;9(7–8):393–397.
   PubMedGoogle Scholar
• Ying T, Feng Y, Wang Y, Chen W, Dimitrov DS. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. MAbs. 2014;6(5):1201–1210. doi:10.4161/mabs.29835
   PubMed Web of Science ®Google Scholar
• Wang C, Wu Y, Wang L, et al. Engineered soluble monomeric IgG1 fc with significantly decreased non-specific binding. Front Immunol. 2017;8:1545. doi:10.3389/fimmu.2017.01545
   PubMed Web of Science ®Google Scholar
• Andersen JT, Dalhus B, Cameron J, et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun. 2012;3:610. doi:10.1038/ncomms1607
   PubMed Web of Science ®Google Scholar
• Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the Interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol. 2014;5:682.
   PubMed Web of Science ®Google Scholar
• Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry. 2006;45(15):4983–4990. doi:10.1021/bi052628y
   PubMed Web of Science ®Google Scholar
• Taguchi K, Chuang VT, Maruyama T, Otagiri M. Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications. J Pharm Sci. 2012;101(9):3033–3046. doi:10.1002/jps.23181
   PubMed Web of Science ®Google Scholar
• Rogers B, Dong D, Li Z, Li Z. Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy. Curr Pharm Des. 2015;21(14):1899–1907. doi:10.2174/1381612821666150302120047
   PubMed Web of Science ®Google Scholar
• Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002;19(5):569–577. doi:10.1023/A:1015396825274
   PubMed Web of Science ®Google Scholar
• Maity N, Jaswal AS, Gautam A, Sahai V, Mishra S. High level production of stable human serum albumin in Pichia pastoris and characterization of the recombinant product. Bioprocess Biosyst Eng. 2022;45(2):409–424. doi:10.1007/s00449-021-02670-z
   PubMed Web of Science ®Google Scholar
• Chuang VT, Otagiri M. Recombinant human serum albumin. Drugs Today (Barc). 2007;43(8):547–561. doi:10.1358/dot.2007.43.8.1067343
   PubMed Web of Science ®Google Scholar
• Sheshukova KA, Wilken LR. Analysis of Recombinant Human Serum Albumin Extraction and Degradation in Transgenic Rice Extracts. Biotechnol Prog. 2018;34(3):681–691. doi:10.1002/btpr.2609
   PubMed Web of Science ®Google Scholar
• Chen Z, He Y, Shi B, Yang D. Human serum albumin from recombinant DNA technology: challenges and strategies. Biochim Biophys Acta. 2013;1830(12):5515–5525. doi:10.1016/j.bbagen.2013.04.037
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, Albiglutide Study G. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32(10):1880–1886. doi:10.2337/dc09-0366
   PubMed Web of Science ®Google Scholar
• Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810–4817. doi:10.1210/jc.2008-1518
   PubMed Web of Science ®Google Scholar
• Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29(10):1260–1267. doi:10.1111/j.1464-5491.2012.03745.x
   PubMed Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–1460. doi:10.1016/j.clinthera.2008.08.006
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225–1231. doi:10.2337/dc11-1935
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:9662):473–481. doi:10.1016/S0140-6736(08)61246-5
   Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529. doi:10.1016/S0140-6736(18)32261-X
   PubMed Web of Science ®Google Scholar
• Ahren B, Johnson SL, Stewart M, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141–2148. doi:10.2337/dc14-0024
   PubMed Web of Science ®Google Scholar
• Weissman PN, Carr MC, Ye J, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014;57(12):2475–2484. doi:10.1007/s00125-014-3360-3
   PubMed Web of Science ®Google Scholar
• Tan H, Su W, Zhang W, Zhang J, Sattler M, Zou P. Albumin-binding domain extends half-life of glucagon-like peptide-1. Eur J Pharmacol. 2021;890:173650. doi:10.1016/j.ejphar.2020.173650
   PubMed Web of Science ®Google Scholar
• Kemp SF, Creech RH, Horn TR. Glycosylated albumin and transferrin: short-term markers of blood glucose control. J Pediatr. 1984;105(3):394–398. doi:10.1016/S0022-3476(84)80011-6
   PubMed Web of Science ®Google Scholar
• Ma Y, Cai J, Wang Y, Liu J, Fu S. Non-Enzymatic Glycation of Transferrin and Diabetes Mellitus. Diabetes Metab Syndr Obes. 2021;14:2539–2548. doi:10.2147/DMSO.S304796
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care. 2007;30(7):1926–1933. doi:10.2337/dc06-2625
   PubMed Web of Science ®Google Scholar
• Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is prospectively associated with insulin resistance and glucose intolerance over a 7-year follow-up period: the CODAM study. Acta Diabetol. 2015;52(2):337–348. doi:10.1007/s00592-014-0646-3
   PubMed Web of Science ®Google Scholar
• Kar M, Chakraborti AS. Release of iron from haemoglobin--a possible source of free radicals in diabetes mellitus. Indian J Exp Biol. 1999;37(2):190–192.
   PubMedGoogle Scholar
• Cooksey RC, Jones D, Gabrielsen S, et al. Dietary iron restriction or iron chelation protects from diabetes and loss of β-cell function in the obese (ob/ob lep −/−) mouse. Am J Physiol Endocrinol Metab. 2010;298(6):E1236–E1243. doi:10.1152/ajpendo.00022.2010
   PubMed Web of Science ®Google Scholar
• Johnsen KB, Burkhart A, Thomsen LB, Andresen TL, Moos T. Targeting the transferrin receptor for brain drug delivery. Prog Neurobiol. 2019;181:101665. doi:10.1016/j.pneurobio.2019.101665
   PubMed Web of Science ®Google Scholar
• Markowicz-Piasecka M, Markiewicz A, Darlak P, et al. Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics. Neurotherapeutics. 2022;19(3):942–976. doi:10.1007/s13311-022-01228-5
   PubMed Web of Science ®Google Scholar
• Chen YS, Zaro JL, Zhang D, Huang N, Simon A, Shen WC. Characterization and oral delivery of proinsulin-transferrin fusion protein expressed using expresstec. Int J Mol Sci. 2018;19:2.
   Web of Science ®Google Scholar
• Banerjee D, Flanagan PR, Cluett J, Valberg LS. Transferrin receptors in the human gastrointestinal tract. Relationship to body iron stores. Gastroenterology. 1986;91(4):861–869. doi:10.1016/0016-5085(86)90687-6
   PubMed Web of Science ®Google Scholar
• Kim BJ, Zhou J, Martin B, et al. Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Ther. 2010;334(3):682–692. doi:10.1124/jpet.110.166470
   PubMed Web of Science ®Google Scholar
• Brandsma ME, Diao H, Wang X, Kohalmi SE, Jevnikar AM, Ma S. Plant-derived recombinant human serum transferrin demonstrates multiple functions. Plant Biotechnol J. 2010;8(4):489–505. doi:10.1111/j.1467-7652.2010.00499.x
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen YS, Zaro JL, Shen WC. Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells. J Control Release. 2011;155(3):386–392. doi:10.1016/j.jconrel.2011.06.029
   PubMed Web of Science ®Google Scholar
• Shao J, Zaro JL, Shen WC. Proinsulin-transferrin fusion protein exhibits a prolonged and selective effect on the control of hepatic glucose production in an experimental model of type 1 diabetes. Mol Pharm. 2016;13(8):2641–2646. doi:10.1021/acs.molpharmaceut.6b00168
   PubMedGoogle Scholar
• Bergenstal RM, Cohen RM, Lever E, et al. The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetes. J Clin Endocrinol Metab. 1984;58(6):973–979. doi:10.1210/jcem-58-6-973
   PubMed Web of Science ®Google Scholar
• Schatz H, Ammermann S, Laube H, Federlin K. Bioactivity and pharmacokinetics of human proinsulin in comparison to human insulin after intravenous and subcutaneous injection. Horm Metab Res. 1988;20(7):445–449. doi:10.1055/s-2007-1010856
   PubMed Web of Science ®Google Scholar
• Given BD, Cohen RM, Shoelson SE, Frank BH, Rubenstein AH, Tager HS. Biochemical and clinical implications of proinsulin conversion intermediates. J Clin Invest. 1985;76(4):1398–1405. doi:10.1172/JCI112116
   PubMed Web of Science ®Google Scholar
• Peavy DE, Abram JD, Frank BH, Duckworth WC. In vitro activity of biosynthetic human proinsulin. Receptor binding and biologic potency of proinsulin and insulin in isolated rat adipocytes. Diabetes. 1984;33(11):1062–1067. doi:10.2337/diab.33.11.1062
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang HY, Zhou L, Su Y, Shen WC. Biodistribution, activation, and retention of proinsulin-transferrin fusion protein in the liver: mechanism of liver-targeting as an insulin prodrug. J Control Release. 2018;275:186–191. doi:10.1016/j.jconrel.2018.02.030
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang HY, Shao J, Zaro JL, Shen WC. Enhanced insulin receptor interaction by a bifunctional insulin-transferrin fusion protein: an approach to overcome insulin resistance. Sci Rep. 2020;10(1):7724. doi:10.1038/s41598-020-64731-9
   PubMed Web of Science ®Google Scholar
• Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3(12):1362–1368. doi:10.1038/nm1297-1362
   PubMed Web of Science ®Google Scholar
• Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65(1):3–13. doi:10.1023/A:1026246500788
   PubMed Web of Science ®Google Scholar
• Chen X, Zaro JL, Shen WC. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013;65(10):1357–1369. doi:10.1016/j.addr.2012.09.039
   PubMed Web of Science ®Google Scholar
• Chen X, Lee HF, Zaro JL, Shen WC. Effects of receptor binding on plasma half-life of bifunctional transferrin fusion proteins. Mol Pharm. 2011;8(2):457–465. doi:10.1021/mp1003064
   PubMedGoogle Scholar
• S O. Fusion protein and biosimilars market report; 2023.
   Google Scholar